162 related articles for article (PubMed ID: 30795780)
1. High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up.
Rutstein SE; Chen JS; Nelson JAE; Phiri S; Miller WC; Hosseinipour MC
AIDS Res Ther; 2019 Feb; 16(1):5. PubMed ID: 30795780
[TBL] [Abstract][Full Text] [Related]
2. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
[TBL] [Abstract][Full Text] [Related]
3. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
[TBL] [Abstract][Full Text] [Related]
4. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Mesplède T; Wainberg MA
Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
[TBL] [Abstract][Full Text] [Related]
5. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
[TBL] [Abstract][Full Text] [Related]
7. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
[TBL] [Abstract][Full Text] [Related]
8. Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
Fulcher JA; Du Y; Zhang TH; Sun R; Landovitz RJ
Clin Infect Dis; 2018 Aug; 67(5):791-794. PubMed ID: 29933437
[TBL] [Abstract][Full Text] [Related]
9. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.
Maphosa T; Dunga S; Makonokaya L; Woelk G; Maida A; Wang A; Ahimbisibwe A; Chamanga RK; Zimba SB; Kayira D; Machekano R
BMC Public Health; 2024 May; 24(1):1321. PubMed ID: 38755632
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
11. Low-cost urine tenofovir assay to triage dolutegravir resistance testing.
Martinson T; Nwogu-Attah J; Spinelli M; Gandhi M
Lancet HIV; 2024 May; 11(5):e282-e283. PubMed ID: 38461845
[No Abstract] [Full Text] [Related]
12. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
13. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.
Ndashimye E; Avino M; Kyeyune F; Nankya I; Gibson RM; Nabulime E; Poon AFY; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
AIDS Res Hum Retroviruses; 2018 May; 34(5):404-414. PubMed ID: 29353487
[TBL] [Abstract][Full Text] [Related]
14. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
Brenner BG; Thomas R; Blanco JL; Ibanescu RI; Oliveira M; Mesplède T; Golubkov O; Roger M; Garcia F; Martinez E; Wainberg MA
J Antimicrob Chemother; 2016 Jul; 71(7):1948-53. PubMed ID: 27029845
[TBL] [Abstract][Full Text] [Related]
15. Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi.
Makonokaya L; Maida A; Kalitera LU; Wang A; Kapanda L; Kayira D; Bottoman M; Nkhoma H; Dunga S; Joaki Z; Chamanga R; Nkanaunena K; Hrapcak S; Nyirenda R; Chiwandira B; Maulidi M; Woelk G; Machekano R; Maphosa T
AIDS Behav; 2024 Jun; 28(6):2148-2155. PubMed ID: 38615099
[TBL] [Abstract][Full Text] [Related]
16. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.
Inzaule SC; Hamers RL; Doherty M; Shafer RW; Bertagnolio S; Rinke de Wit TF
Lancet Infect Dis; 2019 Jul; 19(7):e246-e252. PubMed ID: 30902440
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
[TBL] [Abstract][Full Text] [Related]
18. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.
Castagna A; Ferrara M; Galli L; Comi L; Sterrantino G; Cenderello G; Zaccarelli M; Focà E; Roncadori A; Lazzarin A;
J Antimicrob Chemother; 2018 Jan; 73(1):177-182. PubMed ID: 29077927
[TBL] [Abstract][Full Text] [Related]
20. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
